Tags

Type your tag names separated by a space and hit enter

Allergy to kiwi: a double-blind, placebo-controlled food challenge study in patients from a birch-free area.
J Allergy Clin Immunol 2004; 113(3):543-50JA

Abstract

BACKGROUND

Allergy to kiwi fruit is being increasingly reported, but it has never been evaluated by means of a double-blind, placebo-controlled food challenge (DBPCFC) study.

OBJECTIVE

We sought to assess kiwi allergy on the basis of a DBPCFC and identify the patterns of allergen recognition in sensitized patients from a birch-free area.

METHODS

Forty-three patients with allergy symptoms who were sensitized to kiwi were evaluated by means of clinical history, skin tests, IgE determinations, and DBPCFCs. The pattern of allergen recognition was assessed by means of IgE immunoblotting. Sequence analysis of IgE-binding bands was performed by using Edman degradation.

RESULTS

DBPCFCs were performed in 33 patients; 4 patients had experienced severe anaphylaxis, and 6 patients declined informed consent. DBPCFC results were positive in 23 patients and negative in 10 patients. The most frequent clinical manifestation was oral allergy syndrome. Twenty-one percent of the patients were not allergic to pollen. Forty-six percent of patients experienced systemic symptoms, and this happened with higher frequency in patients not allergic to pollen (100%). Twenty-eight percent of the patients were sensitized to latex. The IgE-binding bands in kiwi extract more frequently recognized by patient sera were those of 30, 24, 66, and 12 kd, and they could not be associated with any pattern of kiwi-induced allergic reactions.

CONCLUSION

The results provide evidence that kiwi allergy is not a homogeneous disorder because several clinical subgroups can be established. No definite allergen-recognition pattern was associated with the type of allergic reactions to kiwi. One of 5 patients with kiwi allergy was not allergic to pollen, and these patients had the highest risk of systemic reactions to kiwi.

Authors+Show Affiliations

Allergy Department, Fundación Jiménez Díaz, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15007359

Citation

Alemán, Ana, et al. "Allergy to Kiwi: a Double-blind, Placebo-controlled Food Challenge Study in Patients From a Birch-free Area." The Journal of Allergy and Clinical Immunology, vol. 113, no. 3, 2004, pp. 543-50.
Alemán A, Sastre J, Quirce S, et al. Allergy to kiwi: a double-blind, placebo-controlled food challenge study in patients from a birch-free area. J Allergy Clin Immunol. 2004;113(3):543-50.
Alemán, A., Sastre, J., Quirce, S., de las Heras, M., Carnés, J., Fernández-Caldas, E., ... Cuesta-Herranz, J. (2004). Allergy to kiwi: a double-blind, placebo-controlled food challenge study in patients from a birch-free area. The Journal of Allergy and Clinical Immunology, 113(3), pp. 543-50.
Alemán A, et al. Allergy to Kiwi: a Double-blind, Placebo-controlled Food Challenge Study in Patients From a Birch-free Area. J Allergy Clin Immunol. 2004;113(3):543-50. PubMed PMID: 15007359.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allergy to kiwi: a double-blind, placebo-controlled food challenge study in patients from a birch-free area. AU - Alemán,Ana, AU - Sastre,Joaquin, AU - Quirce,Santiago, AU - de las Heras,Manuel, AU - Carnés,Jerónimo, AU - Fernández-Caldas,Enrique, AU - Pastor,Carlos, AU - Blázquez,Ana Belén, AU - Vivanco,Fernando, AU - Cuesta-Herranz,Javier, PY - 2004/3/10/pubmed PY - 2004/5/20/medline PY - 2004/3/10/entrez SP - 543 EP - 50 JF - The Journal of allergy and clinical immunology JO - J. Allergy Clin. Immunol. VL - 113 IS - 3 N2 - BACKGROUND: Allergy to kiwi fruit is being increasingly reported, but it has never been evaluated by means of a double-blind, placebo-controlled food challenge (DBPCFC) study. OBJECTIVE: We sought to assess kiwi allergy on the basis of a DBPCFC and identify the patterns of allergen recognition in sensitized patients from a birch-free area. METHODS: Forty-three patients with allergy symptoms who were sensitized to kiwi were evaluated by means of clinical history, skin tests, IgE determinations, and DBPCFCs. The pattern of allergen recognition was assessed by means of IgE immunoblotting. Sequence analysis of IgE-binding bands was performed by using Edman degradation. RESULTS: DBPCFCs were performed in 33 patients; 4 patients had experienced severe anaphylaxis, and 6 patients declined informed consent. DBPCFC results were positive in 23 patients and negative in 10 patients. The most frequent clinical manifestation was oral allergy syndrome. Twenty-one percent of the patients were not allergic to pollen. Forty-six percent of patients experienced systemic symptoms, and this happened with higher frequency in patients not allergic to pollen (100%). Twenty-eight percent of the patients were sensitized to latex. The IgE-binding bands in kiwi extract more frequently recognized by patient sera were those of 30, 24, 66, and 12 kd, and they could not be associated with any pattern of kiwi-induced allergic reactions. CONCLUSION: The results provide evidence that kiwi allergy is not a homogeneous disorder because several clinical subgroups can be established. No definite allergen-recognition pattern was associated with the type of allergic reactions to kiwi. One of 5 patients with kiwi allergy was not allergic to pollen, and these patients had the highest risk of systemic reactions to kiwi. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/15007359/Allergy_to_kiwi:_a_double_blind_placebo_controlled_food_challenge_study_in_patients_from_a_birch_free_area_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091674903028513 DB - PRIME DP - Unbound Medicine ER -